Platinum-based compounds for the treatment of metastatic breast cancer. - Test2 - elhamkhani - TriplyDB

Platinum-based compounds for the treatment of metastatic breast cancer.

Platinum-based compounds for the treatment of metastatic breast cancer.

http://www.wikidata.org/entity/Q37976172

about

MiR-519d impedes cisplatin-resistance in breast cancer stem cells by down-regulating the expression of MCL-1 Human breast cancer and lymph node metastases express Gb3 and can be targeted by STxB-vectorized chemotherapeutic compounds.Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer Autophagy Inhibition Delays Early but Not Late-Stage Metastatic Disease.N-Myc and STAT Interactor regulates autophagy and chemosensitivity in breast cancer cells.A novel role for the anti-senescence factor TBX2 in DNA repair and cisplatin resistance Targeting NF-κB/AP-2β signaling to enhance antitumor activity of cisplatin by melatonin in hepatocellular carcinoma cells.Platinum-containing regimens for metastatic breast cancer.Effects of fusaric acid treatment on HEp2 and docetaxel-resistant HEp2 laryngeal squamous cell carcinoma.Reduced Newcastle disease virus-induced oncolysis in a subpopulation of cisplatin-resistant MCF7 cells is associated with survivin stabilization Rapamycin inhibits prostate cancer cell growth through cyclin D1 and enhances the cytotoxic efficacy of cisplatin.Differential pathological response to preoperative chemotherapy across breast cancer intrinsic subtypes.Ototoxicity monitoring through the eyes of the treating physician: Perspectives from pulmonology and medical oncology.Role of BRCA Mutations in the Modulation of Response to Platinum Therapy.ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway.

P2860

Q33591783-A1CB806C-D76A-4AFF-9B92-FB8E61AF91E6 Q34897367-7B40EAD4-3E65-4333-9EB8-FE2256367279 Q35987082-4B457352-8B48-4141-A831-8F5C331CF78B Q36031947-74DEACC5-E31E-4C91-A260-2F5B5F7F584D Q36288362-A0F08AF7-7FA1-4A29-BEB3-72D5D529F119 Q37299652-AA296EC2-B32C-43BB-AF7A-A9272B50D3AF Q37596811-5494739C-E1EE-4445-959A-663E87258D91 Q38712631-5BEC4066-DA52-4D66-A5FA-F6943B04A0F6 Q39093935-1EAE2A50-9CC2-430D-B9EC-6D1E34C5C50C Q39304159-AE5CC2B7-CA74-4AC2-B93B-88D052D04230 Q40970978-F6335309-EA41-441A-B229-0527208E42D2 Q42517316-D7041C66-0D99-42CB-96D1-4A46C481651C Q48244389-3348ECE8-F4AD-49DA-9BCA-C96C463BD4DA Q49829001-A613D814-7036-434B-8DEC-650445811D32 Q55435917-F0F0DC86-677B-41F9-9AC9-A9CB8F6320E3

P2860

Platinum-based compounds for the treatment of metastatic breast cancer.

http://www.wikidata.org/entity/Q37976172

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Platinum-based compounds for the treatment of metastatic breast cancer.

@en

Platinum-based compounds for the treatment of metastatic breast cancer.

@nl

type

label

Platinum-based compounds for the treatment of metastatic breast cancer.

@en

Platinum-based compounds for the treatment of metastatic breast cancer.

@nl

prefLabel

Platinum-based compounds for the treatment of metastatic breast cancer.

@en

Platinum-based compounds for the treatment of metastatic breast cancer.

@nl

P1433

Q37976172-1E7E68E0-6BDC-4FD4-B5BD-08BEBB7D478F

P1476

Q37976172-BD69E1DD-14E6-4096-BEF3-69BD078BC8A2

P2093

Q37976172-07BB01FC-7C05-4B97-A171-483FD26E6FF5

Q37976172-4007136A-2E86-4D3D-8A4E-BC4D69B9DEB2

P2860

Q37976172-00A605E3-2BEA-46FA-B29F-4AF242EB3F65

Q37976172-0263493A-C54A-4F25-AC55-B2F46D4D5F5B

Q37976172-033483E7-411A-4719-AFD8-BB4C27270E24

Q37976172-035C198A-02FE-48A0-B3BA-1F70101CBA90

Q37976172-061DBC0A-B359-41F5-ADFA-BE7B0571F1B9

Q37976172-08FF885C-5B03-4842-8021-C2DBB243C63B

Q37976172-09CB10BB-FDBF-4037-83A7-B4C8C70F183F

Q37976172-0FDFF6B5-3A44-4C59-8824-3D0BD13CD525

Q37976172-13428283-4E33-4476-BA90-616BA036E3BA

Q37976172-1E3E5232-35AA-4350-8274-DFBF058BCB95

P304

Q37976172-435913E9-6A23-4F84-A802-CBACF325CC7A

P31

Q37976172-EDD6CAD3-F528-468E-9599-7598F69EEFEE

P356

Q37976172-D759E816-85C3-45A8-B87A-EC08571D28D2

P433

Q37976172-40F16EE5-EB4B-4106-8081-3E96E92740B8

P478

Q37976172-7B8FFDD5-E275-478D-8DDC-CDD6EC39BF3F

P577

Q37976172-66F506AA-E87A-4521-B0B6-1A8A09199925

P698

Q37976172-93497ECD-8A09-4D48-ADA8-9D72EA40A41C

P356

P1433

P1476

Platinum-based compounds for the treatment of metastatic breast cancer.

@en

P2093

Ali I Shamseddine

http://www.w3.org/2001/XMLSchema#string

Fadi S Farhat

http://www.w3.org/2001/XMLSchema#string

P2860

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial

A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer

Clinical activity of cisplatin and prolonged oral administration of etoposide in previously treated, anthracycline-resistant, metastatic breast cancer patients: a phase II study

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

EGFR associated expression profiles vary with breast tumor subtype

Phase II study of carboplatin and etoposide as salvage treatment for patients with metastatic breast cancer.

Combination cisplatin-vinorelbine for relapsed and chemotherapy-pretreated metastatic breast cancer.

Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer.

Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study.

P304

468-487

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000334093

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22248721

http://www.w3.org/2001/XMLSchema#string